The omega-3
market is estimated to be USD 4,362.2 million in 2025 and is projected
to reach USD 7,756.4 million by 2030, at a CAGR of 12.2% from 2025 to 2030.
Demand for omega-3 is projected to grow significantly as consumers become more
aware of its role in supporting cardiovascular, cognitive, eye, and joint
health. Unlike several other nutrients, omega-3 fatty acids, such as EPA and
DHA, cannot be synthesized efficiently by the human body, resulting in
increased reliance on dietary supplements, fortified foods, and pharmaceutical-grade
formulations. Omega-3 oils are highly versatile and can be incorporated into
capsules, powders, beverages, and functional foods while maintaining stability
and efficacy. Fish oil, krill oil, and algal-based omega-3 are the most
preferred sources, backed by scientific validation of their safety and
effectiveness. The growing popularity among health-conscious consumers, coupled
with increasing demand for clean-label and sustainable products, is expected to
further strengthen the outlook for the omega-3 market in the coming years.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=227
By type, DHA segment to exhibit fastest
growth rate during forecast period.
Docosahexaenoic acid (DHA), a polyunsaturated omega-3
fatty acid (PUFA), is widely distributed throughout the body and has emerged as
the leading type segment in the omega-3 market. It serves as a significant
structural fat present in both the brain and eye, constituting as much as 97%
of the total omega-3 fats in the brain and up to 93% in the retina. The main
sources of DHA are fish, fish oils, dairy products, and specialty eggs, with
marine sources such as salmon and tuna being particularly rich. Farmed salmon
contains about 1.24 g of DHA, and wild salmon about 1.22 g of DHA.
Additionally, DHA is a crucial component of cardiac
tissue and is also commonly referred to as 22:6(n-3). Direct consumption of DHA
is necessary to effectively increase fatty acid levels in the body, and optimal
intake is crucial for both infant brain development and normal adult brain
function. Epidemiological research further associates healthy DHA intake with a
reduced risk of Alzheimer’s disease, as DHA improves communication between
nerve cells and membranes by enhancing fluidity. Its critical role in visual
and neurological development in infants, coupled with widespread applications
in infant nutrition, dietary supplements, and functional foods, has solidified
DHA as the dominating segment within the omega-3 market. The growing demand
from both developed and emerging economies ensures that DHA continues to hold a
substantial market share compared to other omega-3 types, such as EPA and ALA.
By application, infant formulas segment to
record highest CAGR during forecast period.
The infant formulas segment is anticipated to grow at a
significant rate in the omega-3 market due to the rising recognition of DHA’s
crucial role in infant brain and eye development. DHA, often referred to as the
“brain-building” omega-3, is recommended by leading health authorities such as
the World Health Organization (WHO) and the European Food Safety Authority
(EFSA) for inclusion in infant nutrition. With an increasing number of working
mothers and a higher reliance on formula feeding, demand for fortified infant
formulas containing DHA and EPA has surged worldwide. Manufacturers are
consistently innovating by introducing premium formulas that mimic the fatty
acid composition of human breast milk, further boosting adoption. Regulatory
mandates in many regions, such as the EU’s requirement since 2020 for DHA
inclusion in all infant formula and follow-on formula products, have led to the
European Union (EU) implementing new regulations, effective February 22, 2021,
regarding the recommended DHA supplementation in healthy diets. These
regulations mandate that all infant formula and follow-on formula available for
purchase within the EU must contain a minimum of 20 mg/100 kcal (or 4.8 mg/100
kJ) and a maximum of 50 mg/100 kcal (or 128 mg/100 kJ) of DHA, which is
accelerating market growth. In addition, growing consumer preference for
organic and clean-label formulas, along with strong demand in emerging
economies driven by rising birth rates and improved purchasing power, is
expected to fuel the segment's expansion during the forecast period.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=227
Europe to account for significant share in
global omega-3 market.
Europe is expected to hold a significant share of the
omega-3 market, driven by a robust regulatory framework, high consumer
awareness, and a growing preference for preventive healthcare. Additionally,
European consumers show a higher inclination toward premium dietary supplements
and clean-label products, fostering demand for sustainable fish oil and
plant/algal-based omega-3 alternatives. The presence of major global players,
continuous research and development initiatives, and widespread adoption of fortified
foods and beverages further strengthen Europe’s dominance. Moreover, increasing
vegetarian and flexitarian populations in countries such as Germany, the UK,
and France are accelerating the demand for algal-derived omega-3, ensuring
steady market growth across the region. According to the European Food Safety
Authority (EFSA), micronutrients present in omega-3s even benefit eye and brain
health, which has led to heavy focus and a surge in consumption among
Europeans. Companies such as Pelagia AS (Norway), Corbion (Netherlands), and
dsm-firmenich (Netherlands) are the key players that are highly focused on
catering to the demand for omega-3-based products in the European region. In
2023, several recent advancements were observed in the omega-3 market within
the European region. Corbion (Netherlands) launched a new product, AlgaVia,
whereas Pelagia AS (Norway) invested in its production facility to increase the
output of the omega-3 concentrates.
The European Society of Cardiology (ESC) has had a
significant impact on the omega-3 market in the European region, as its studies
emphasize that omega-3 consumption helps decrease the risk of cardiovascular
diseases. European omega-3 manufacturers are investing in omega-3 applications,
such as dietary supplements, functional food & beverages, and
pharmaceuticals. BASF SE (Germany) offers microencapsulated omega-3 powder with
more shelf life to cater to the European demand. Furthermore, the rise in consumer
awareness has prompted manufacturers to follow and adhere to European
regulations, which is projected to drive growth in Europe.
Leading Omega-3
Manufacturers:
The report profiles key players such as BASF SE
(Germany), Cargill, Incorporated (US), dsm-firmenich (Netherlands), ADM (US),
Kerry Group plc (Ireland), Aker BioMarine (Norway), Croda International plc
(UK), Corbion (Netherlands), Pelagia AS (Norway), KD Pharma Group SA
(Switzerland), GC Rieber (Norway), Cooke Aquaculture Inc. (Canada), GOLDEN
OMEGA (Chile), Polaris (France), Btsa (Spain), KinOmega Biopharm Inc. (China),
Rimfrost AS (Norway), Mara Renewables (Canada), Cellana Inc. (US), AlgaeCytes
Limited (UK), and others.
No comments:
Post a Comment